Drug
Ubrogepant
Ubrogepant: highest development phase Phase 3, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ubrogepant NCT05127954 | Phase 3 | Migraine |
Latest
No recent events.
Follow Ubrogepant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.